Top

BMC Cancer

Published in:

Open Access 01-12-2009 | Research article

Overexpression of UbcH10 alternates the cell cycle profile and accelerate the tumor proliferation in colon cancer

Authors: Takeo Fujita, Hirokuni Ikeda, Naruto Taira, Shinji Hatoh, Minoru Naito, Hiroyoshi Doihara

Published in: BMC Cancer | Issue 1/2009

Abstract

Background

UbcH10 participates in proper metaphase to anaphase transition, and abrogation of UbcH10 results in the premature separation of sister chromatids. To assess the potential role of UbcH10 in colon cancer progression, we analyzed the clinicopathological relevance of UbcH10 in colon cancer.

Methods

We firstly screened the expression profile of UbcH10 in various types of cancer tissues as well as cell lines. Thereafter, using the colon cancer cells line, we manipulated the expression of UbcH10 and evaluated the cell cycle profile and cellular proliferations. Furthermore, the clinicopathological significance of UbcH10 was immunohistologically evaluated in patients with colon cancer. Statistical analysis was performed using the student's t-test and Chi-square test.

Results

Using the colon cancer cells, depletion of UbcH10 resulted in suppression of cellular growth whereas overexpression of UbcH10 promoted the cellular growth and oncogenic cellular growth. Mitotic population was markedly alternated by the manipulation of UbcH10 expression. Immunohistochemical analysis indicated that UbcH10 was significantly higher in colon cancer tissue compared with normal colon epithelia. Furthermore, the clinicopathological evaluation revealed that UbcH10 was associated with high-grade histological tumors.

Conclusion

The results show the clinicopathological significance of UbcH10 in the progression of colon cancer. Thus UbcH10 may act as a novel biomarker in patients with colon cancer.

Available only for authorised users

Yamasaki L, Pagano M: Cell cycle, proteolysis and cancer. Curr Opin Cell Biol. 2004, 16 (6): 623-628. 10.1016/j.ceb.2004.08.005.CrossRefPubMed

Pagano M: Cell cycle regulation by the ubiquitin pathway. Faseb J. 1997, 11 (13): 1067-1075.PubMed

Weissman AM: Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol. 2001, 2 (3): 169-178. 10.1038/35056563.CrossRefPubMed

Hoeller D, Hecker CM, Dikic I: Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer. 2006, 6 (10): 776-788. 10.1038/nrc1994.CrossRefPubMed

Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Graetta GE, Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995, 269 (5224): 682-85. 10.1126/science.7624798.CrossRefPubMed

Sutterluty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Muller U, Krek W: p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol. 1999, 1 (4): 207-214. 10.1038/12027.CrossRefPubMed

Hsu JY, Reimann JD, Sorensen CS, Lukas J, Jackson PK: E2F-dependent accumulation of hEmi1 regulates S phase entry by inhibiting APC(Cdh1). Nat Cell Biol. 2002, 4 (5): 358-366. 10.1038/ncb785.CrossRefPubMed

Reimann JD, Gardner BE, Margottin-Goguet F, Jackson PK: Emi1 is a mitotic regulator that interacts with Cdc20 and inhibits the anaphase promoting complex. Gene Dev. 2001, 15 (24): 645-655. 10.1101/gad.945701.CrossRef

de Gramont A, Ganier O, Cohen-Fix O: Before and after the spindle assembly checkpoint: An APC/C Point of View. Cell Cycle. 2006, 5 (18): 2168-2171.CrossRefPubMed

10.

Rape M, Reddy SK, Kirschner MW: The processivity of multiubiquitination by the APC determinies the order of substrate degradation. Cell. 2006, 124 (1): 89-103. 10.1016/j.cell.2005.10.032.CrossRefPubMed

11.

Summers MK, Pan B, Mukhyala K, Jackson PK: The unique N terminus of the UbcH10 E2 enzyme controls the threshold for APC activation and enhances checkpoint regulation of the APC. Mol Cell. 2008, 31 (4): 544-556. 10.1016/j.molcel.2008.07.014.CrossRefPubMedPubMedCentral

12.

Kriegenburg F, Seeger M, Saeki Y, Tanaka K, Lauridsen AM, Hartmann-Petersen R, Hendil B: Mammalian 26S proteasomes remain intact during protein degradation. Cell. 2008, 135 (2): 355-365. 10.1016/j.cell.2008.08.032.CrossRefPubMed

13.

Kienitz A, Vogel C, Morales I, Muller R, Bastians H: Partial downregulation of MAD1 causes spindle checkpoint inactivation and aneuploidy, but does not confer resistance towards taxol. Oncogene. 2005, 24 (26): 4301-4310. 10.1038/sj.onc.1208589.CrossRefPubMed

14.

Hernando F, Orlow I, Liberal V, Nohales G, Benezra R, Cordon-Cardo C: Molecular analyses of the mitotic checkpoint components hsMAD2, hBUB1 and hBUB3 in human cancer. Int J Cancer. 2001, 95 (4): 223-227. 10.1002/1097-0215(20010720)95:4<223::AID-IJC1038>3.0.CO;2-L.CrossRefPubMed

15.

Meraldi P, Honda R, Nigg EA: Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev. 2004, 95 (4): 29-36. 10.1016/j.gde.2003.11.006.CrossRef

16.

Anand S, Penrhyn-Lowe S, Venkitaraman AR: AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell. 2003, 3 (1): 51-62. 10.1016/S1535-6108(02)00235-0.CrossRefPubMed

17.

Weaver BA, Cleveland DW: Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell. 2005, 8 (1): 7-12. 10.1016/j.ccr.2005.06.011.CrossRefPubMed

18.

Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M, Nakagawara A: UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res. 2003, 63 (14): 4167-4173.PubMed

19.

Pallante P, Berlingieri MT, Troncone G, Kruhoffer M, Orntoft TF, viglietto G, Caleo A, Migliaccio I, Decaussin-Petrucci M, Santoro M, Palombini L, et al: UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas. Br J Cancer. 2005, 93 (4): 464-471. 10.1038/sj.bjc.6602721.CrossRefPubMedPubMedCentral

20.

Townsley FM, Aristarkhov A, Beck S, Hershko A, Ruderman JV: Dominant negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. Proc Natl Acad USA. 1997, 94 (6): 2362-2367. 10.1073/pnas.94.6.2362.CrossRef

21.

Kolligs FT, Hu G, Dang CV, Fearon ER: Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of cmyc expression. Mol Cell Biol. 1999, 19 (8): 5696-5706.CrossRefPubMedPubMedCentral

22.

Zhang F, Lundin M, Ristimaki A, Heikkila P, Lundin J, Isola J, Joensuu H, Laiho M: Ski-related novel protein N(SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Res. 63 (16): 5005-5010.

23.

Lin Y, Hwang WC, Basavappa R: Structural and functional analysis of human mitotic specific ubiquitin-conjugating enzyme, UbcH10. J Biol Chem. 2002, 277 (24): 21913-21921. 10.1074/jbc.M109398200.CrossRefPubMed

24.

Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, Monti F, Loda M, Pagano M: Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest. 2002, 110 (5): 633-641.CrossRefPubMedPubMedCentral

25.

Wang Q, Moyret-Lalle C, Couzon F, Surbiguet-Clippe C, Saurin JC, Lorca T, Navarro C, Puisieux A: Alterations of anaphase-promoting complex genes in human colon cancer cells. Oncogene. 2003, 22 (10): 1486-1490. 10.1038/sj.onc.1206224.CrossRefPubMed

26.

Wang CX, Fisk BC, Wadehra M, Su H, Braun J: Overexpression of murine fizzy related(fzr) increases natural killer cell-mediated cell death and suppresses tumor growth. Blood. 2000, 96 (1): 259-263.PubMed

27.

Wagner KW, Sapinoso LM, El-Rifai W, Frierson HF, Butz N, Mestan J, Hofmann F, Deveraux QL, Hampton GM: Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene. 2004, 23 (39): 6621-6629. 10.1038/sj.onc.1207861.CrossRefPubMed

28.

Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, et al: Gene expression profiling in breast cancer: understading the molecules basis of histological grade to improve prognosis. J Natl Cancer Inst. 2006, 98 (4): 262-272.CrossRefPubMed

29.

Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette T, Pistone M, Stecker K, Zhang BM, et al: Gene expression profiles of human breast cancer progression. Proc Natl Acad USA. 2003, 100 (10): 5974-5979. 10.1073/pnas.0931261100.CrossRef

30.

Lee JJ, Au AY, Foukakis T, Barbaro M, Kiss M, Clifton-Bligh R, Staaf J, Borg A, Deibridge L, Robinson BG, Wallin G, Höög A, Larsson C: Array-CGH identifies cyclin D1 and UbcH10 amplicons in anaplastic thyroid carcinoma. Endocr Relat Cancer. 2008, 15 (3): 801-815. 10.1677/ERC-08-0018.CrossRefPubMed

31.

Donato G, Iofrida G, Lavano A, Volpentesta G, Signorelli F, Pallante PL, Berlingieri MT, Pierantoni MG, Palmieri D, Conforti F, et al: Analysis of UbcH10 expression represents a useful tool for the diagnosis and therapy of astrocytic tumors. Clin Neuropathol. 2008, 27 (4): 219-223.CrossRefPubMed

32.

Jiang L, Huang CG, Lu YC, Luo C, Hu GH, Liu HM, Chen JX, Han HX: Expression of ubiquitin-conjugating enzyme E2C/UbcH10 in astrocytic tumors. Brain Res. 2008, 1201: 161-166. 10.1016/j.brainres.2008.01.037.CrossRefPubMed

33.

Fujita T, Ikeda H, Kawasaki K, Taira N, Ogasawara Y, Nakagawara A, Doihara H: Clinicopathological relevance of UbcH10 in breast cancer. Cancer Sci. 2008,

34.

Yang M, Li B, Tomchick DR, Machius M, Rizo J, Yu H, Luo X: p31comet blocks Mad2 activation through structural mimicry. Cell. 2007, 131 (4): 744-755. 10.1016/j.cell.2007.08.048.CrossRefPubMedPubMedCentral

35.

Yun MY, Kim SB, Park S, Han CJ, Han YH, Yoon SH, Kim SH, Kim CM, Choi DW, Cho MH, et al: Mutation analysis of p31comet gene, a negative regulator of Mad2, in human hepatocellular carcinoma. Exp Mol Med. 2007, 39 (4): 508-513.CrossRefPubMed

36.

Stegmeier F, Rape M, Draviam VM, Nalepa G, Ang XL, McDonald ER, Li MZ, Hannon GJ, Sorger PK, Kirschner MW, et al: Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities. Nature. 2007, 446 (7138): 876-881. 10.1038/nature05694.CrossRefPubMed

37.

Walker A, Acquaviva C, Matsuoka T, Koop L, Pines J: UbcH10 has a rate-limiting role in G1 phase but might not act in the spindle checkpoint or as part of an autonomous oscillator. J Cell Sci. 2008, 121 (14): 2319-2326. 10.1242/jcs.031591.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/9/87/prepub

Title: Overexpression of UbcH10 alternates the cell cycle profile and accelerate the tumor proliferation in colon cancer
Authors: Takeo Fujita
Hirokuni Ikeda
Naruto Taira
Shinji Hatoh
Minoru Naito
Hiroyoshi Doihara
Publication date: 01-12-2009
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-9-87

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2009

A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivoglioblastoma models

Expression of Hyaluronan Synthases (HAS1–3) and Hyaluronidases (HYAL1–2) in Serous Ovarian Carcinomas: Inverse Correlation between HYAL1 and Hyaluronan Content

The carboxyl terminal trimer of procollagen I induces pro-metastatic changes and vascularization in breast cancer cells xenografts

FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer

Loss of full length CtBP1 expression enhances the invasive potential of human melanoma

Loss of prostasin (PRSS8) in human bladder transitional cell carcinoma cell lines is associated with epithelial-mesenchymal transition (EMT)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer